Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Izotropic ( (TSE:IZO) ) has issued an update.
Izotropic Corporation announced that its CEO, Robert Thast, will present at the Small Cap Growth Virtual Investor Conference, where he will discuss the company’s value proposition, recent achievements, regulatory approvals, and funding options. This event marks the first public presentation of Izotropic’s new regulatory strategy for U.S. FDA approval of its breast CT imaging system, IzoView, which aims to enhance breast cancer screening, particularly for patients with dense breast tissue.
More about Izotropic
Izotropic Corporation is a medical device company focused on commercializing imaging-based products that utilize innovative and emerging technologies for the accurate screening, diagnosis, and treatment of breast cancers.
YTD Price Performance: 182.69%
Average Trading Volume: 56,743
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $8.09M
Find detailed analytics on IZO stock on TipRanks’ Stock Analysis page.
